Published in Lancet Oncol on February 01, 2007
Assessment of the spatial pattern of colorectal tumour perfusion estimated at perfusion CT using two-dimensional fractal analysis. Eur Radiol (2009) 1.70
Current status and guidelines for the assessment of tumour vascular support with dynamic contrast-enhanced computed tomography. Eur Radiol (2012) 1.38
The therapeutic potential of targeting endogenous inhibitors of nitric oxide synthesis. Nat Rev Drug Discov (2011) 1.21
Comprehensive identification and modified-site mapping of S-nitrosylated targets in prostate epithelial cells. PLoS One (2010) 1.10
Endothelin B receptor, a new target in cancer immune therapy. Clin Cancer Res (2009) 1.05
CT perfusion in oncology: how to do it. Cancer Imaging (2010) 1.00
Clinical biomarkers of angiogenesis inhibition. Cancer Metastasis Rev (2008) 0.98
The role of tumour-derived iNOS in tumour progression and angiogenesis. Br J Cancer (2010) 0.97
Radiation dose from volumetric helical perfusion CT of the thorax, abdomen or pelvis. Eur Radiol (2010) 0.97
Gasotransmitters in cancer: from pathophysiology to experimental therapy. Nat Rev Drug Discov (2015) 0.96
Beyond antiangiogenesis: vascular modulation as an anticancer therapy-a review. Transl Oncol (2012) 0.95
Can perfusion CT assessment of primary colorectal adenocarcinoma blood flow at staging predict for subsequent metastatic disease? A pilot study. Eur Radiol (2008) 0.94
Six degrees of separation: the oxygen effect in the development of radiosensitizers. Transl Oncol (2011) 0.94
Thrombospondin 1 and vasoactive agents indirectly alter tumor blood flow. Neoplasia (2008) 0.92
Dynamic contrast-enhanced CT in patients treated with sorafenib and erlotinib for non-small cell lung cancer: a new method of monitoring treatment? Eur Radiol (2010) 0.92
Nitric oxide synthase gene polymorphisms and prostate cancer risk. Carcinogenesis (2009) 0.91
NO to cancer: The complex and multifaceted role of nitric oxide and the epigenetic nitric oxide donor, RRx-001. Redox Biol (2015) 0.90
iNOS: a potential therapeutic target for malignant glioma. Curr Mol Med (2013) 0.89
Collagen IV contributes to nitric oxide-induced angiogenesis of lung endothelial cells. Am J Physiol Cell Physiol (2011) 0.88
Nitric oxide: perspectives and emerging studies of a well known cytotoxin. Int J Mol Sci (2010) 0.84
Is Nitric Oxide (NO) the Last Word in Radiosensitization? A Review. Transl Oncol (2012) 0.84
Nitric oxide synthase inhibition enhances the antitumor effect of radiation in the treatment of squamous carcinoma xenografts. PLoS One (2011) 0.83
Oxidative and nitrosative stress in the metastatic microenvironment. Cancers (Basel) (2010) 0.83
Roles of tetrahydrobiopterin in promoting tumor angiogenesis. Am J Pathol (2010) 0.82
The endothelial ADMA/NO pathway in hypoxia-related chronic respiratory diseases. Biomed Res Int (2014) 0.81
NOS Inhibition Modulates Immune Polarization and Improves Radiation-Induced Tumor Growth Delay. Cancer Res (2015) 0.81
Gr-1+CD11b+ cells facilitate Lewis lung cancer recurrence by enhancing neovasculature after local irradiation. Sci Rep (2014) 0.79
Production of nitric oxide and expression of inducible nitric oxide synthase in ovarian cystic tumors. Mediators Inflamm (2009) 0.78
Nitric oxide synthase inhibition and cancer. Lancet Oncol (2007) 0.77
The implications of hyponitroxia in cancer. Transl Oncol (2014) 0.76
Differential diagnostic value of computed tomography perfusion combined with vascular endothelial growth factor expression in head and neck lesions. Oncol Lett (2016) 0.75
Targeting the tumour vasculature: exploitation of low oxygenation and sensitivity to NOS inhibition by treatment with a hypoxic cytotoxin. PLoS One (2013) 0.75
Fine-Tuning Tumor Endothelial Cells to Selectively Kill Cancer. Int J Mol Sci (2017) 0.75
Magnetic resonance imaging for the detection, localisation, and characterisation of prostate cancer: recommendations from a European consensus meeting. Eur Urol (2010) 4.45
Myocardial infarction mortality risk after treatment for Hodgkin disease: a collaborative British cohort study. J Natl Cancer Inst (2007) 2.65
Combretastatin A4 phosphate has tumor antivascular activity in rat and man as demonstrated by dynamic magnetic resonance imaging. J Clin Oncol (2003) 2.35
Assessment of tumor heterogeneity: an emerging imaging tool for clinical practice? Insights Imaging (2012) 2.31
Hyperfractionated or accelerated radiotherapy in lung cancer: an individual patient data meta-analysis. J Clin Oncol (2012) 2.15
Are pretreatment 18F-FDG PET tumor textural features in non-small cell lung cancer associated with response and survival after chemoradiotherapy? J Nucl Med (2012) 2.14
Pelvic MRI for guiding treatment decisions in rectal cancer. Oncology (Williston Park) (2014) 2.07
Non-small cell lung cancer: histopathologic correlates for texture parameters at CT. Radiology (2012) 2.00
Optimizing colonic distention for multi-detector row CT colonography: effect of hyoscine butylbromide and rectal balloon catheter. Radiology (2003) 1.96
Critical research gaps and translational priorities for the successful prevention and treatment of breast cancer. Breast Cancer Res (2013) 1.92
Lung cancer perfusion at multi-detector row CT: reproducibility of whole tumor quantitative measurements. Radiology (2006) 1.91
Epidermal growth factor receptor expression in pretreatment biopsies from head and neck squamous cell carcinoma as a predictive factor for a benefit from accelerated radiation therapy in a randomized controlled trial. J Clin Oncol (2005) 1.90
Phase I clinical trial of weekly combretastatin A4 phosphate: clinical and pharmacokinetic results. J Clin Oncol (2003) 1.90
Leukocyte DNA damage after multi-detector row CT: a quantitative biomarker of low-level radiation exposure. Radiology (2007) 1.82
CT response assessment combining reduction in both size and arterial phase density correlates with time to progression in metastatic renal cancer patients treated with targeted therapies. Cancer Biol Ther (2010) 1.80
Evaluation of five radiation schedules and prognostic factors for metastatic spinal cord compression. J Clin Oncol (2005) 1.77
Breast cancer risk after supradiaphragmatic radiotherapy for Hodgkin's lymphoma in England and Wales: a National Cohort Study. J Clin Oncol (2012) 1.77
Prognostic factors for local control and survival after radiotherapy of metastatic spinal cord compression. J Clin Oncol (2006) 1.76
Quantifying tumour heterogeneity in 18F-FDG PET/CT imaging by texture analysis. Eur J Nucl Med Mol Imaging (2012) 1.75
Samarium-153-Lexidronam complex for treatment of painful bone metastases in hormone-refractory prostate cancer. Urology (2004) 1.67
TIE2-expressing macrophages limit the therapeutic efficacy of the vascular-disrupting agent combretastatin A4 phosphate in mice. J Clin Invest (2011) 1.66
Antivascular effects of neoadjuvant androgen deprivation for prostate cancer: an in vivo human study using susceptibility and relaxivity dynamic MRI. Int J Radiat Oncol Biol Phys (2010) 1.64
Polyp detection with CT colonography: primary 3D endoluminal analysis versus primary 2D transverse analysis with computer-assisted reader software. Radiology (2006) 1.50
ZD6126: a novel vascular-targeting agent that causes selective destruction of tumor vasculature. Cancer Res (2002) 1.47
Assessment of primary colorectal cancer heterogeneity by using whole-tumor texture analysis: contrast-enhanced CT texture as a biomarker of 5-year survival. Radiology (2012) 1.46
Loss of expression of the tumour suppressor gene AIMP3 predicts survival following radiotherapy in muscle-invasive bladder cancer. Int J Cancer (2014) 1.45
Radiotherapy with concurrent carbogen and nicotinamide in bladder carcinoma. J Clin Oncol (2010) 1.40
Effects of acute versus chronic hypoxia on DNA damage responses and genomic instability. Cancer Res (2010) 1.35
Second cancer risk after chemotherapy for Hodgkin's lymphoma: a collaborative British cohort study. J Clin Oncol (2011) 1.30
Randomized trial of 8 Gy in 1 versus 20 Gy in 5 fractions of radiotherapy for neuropathic pain due to bone metastases (Trans-Tasman Radiation Oncology Group, TROG 96.05). Radiother Oncol (2004) 1.25
Microtubule depolymerizing vascular disrupting agents: novel therapeutic agents for oncology and other pathologies. Int J Exp Pathol (2009) 1.25
Risk of second malignancy after non-Hodgkin's lymphoma: a British Cohort Study. J Clin Oncol (2006) 1.24
Hypoxia in prostate cancer: correlation of BOLD-MRI with pimonidazole immunohistochemistry-initial observations. Int J Radiat Oncol Biol Phys (2007) 1.22
Reactivity of hydrogen sulfide with peroxynitrite and other oxidants of biological interest. Free Radic Biol Med (2010) 1.19
Quantitative assessment of lung cancer perfusion using MDCT: does measurement reproducibility improve with greater tumor volume coverage? AJR Am J Roentgenol (2006) 1.19
Evaluation of the anti-vascular effects of combretastatin in rodent tumours by dynamic contrast enhanced MRI. NMR Biomed (2002) 1.16
From bench to bedside for gene-directed enzyme prodrug therapy of cancer. Anticancer Drugs (2005) 1.12
Target validation of cytochrome P450 CYP1B1 in prostate carcinoma with protein expression in associated hyperplastic and premalignant tissue. Int J Radiat Oncol Biol Phys (2004) 1.08
The vascular response of tumor and normal tissues in the rat to the vascular targeting agent, combretastatin A-4-phosphate, at clinically relevant doses. Int J Oncol (2002) 1.08
Break-induced ATR and Ddb1-Cul4(Cdt)² ubiquitin ligase-dependent nucleotide synthesis promotes homologous recombination repair in fission yeast. Genes Dev (2010) 1.08
Assessment of sarcopenia and changes in body composition after neoadjuvant chemotherapy and associations with clinical outcomes in oesophageal cancer. Eur Radiol (2014) 1.05
Three-dimensional distribution of radiation within the breast: an intercomparison of departments participating in the START trial of breast radiotherapy fractionation. Int J Radiat Oncol Biol Phys (2003) 1.05
Tumor antivascular effects of radiotherapy combined with combretastatin a4 phosphate in human non-small-cell lung cancer. Int J Radiat Oncol Biol Phys (2007) 1.04
High-dose-rate brachytherapy alone for localized prostate cancer in patients at moderate or high risk of biochemical recurrence. Int J Radiat Oncol Biol Phys (2011) 1.04
Thiyl radicals react with nitric oxide to form S-nitrosothiols with rate constants near the diffusion-controlled limit. Free Radic Biol Med (2008) 1.03
The use of in vivo thermoluminescent dosimeters in the quality assurance programme for the START breast fractionation trial. Radiother Oncol (2004) 1.03
Assessment of tumor heterogeneity by CT texture analysis: can the largest cross-sectional area be used as an alternative to whole tumor analysis? Eur J Radiol (2012) 1.03
Validation and simplification of a score predicting survival in patients irradiated for metastatic spinal cord compression. Cancer (2010) 1.02
Do anti-angiogenic VEGF (VEGFxxxb) isoforms exist? A cautionary tale. PLoS One (2012) 1.02
Justification for inter-fraction correction of catheter movement in fractionated high dose-rate brachytherapy treatment of prostate cancer. Radiother Oncol (2009) 1.02
Tumour targeting by microtubule-depolymerizing vascular disrupting agents. Expert Opin Ther Targets (2007) 1.01
Oxygen regulation of tumor perfusion by S-nitrosohemoglobin reveals a pressor activity of nitric oxide. Circ Res (2005) 1.00
Conventional second-line salvage chemotherapy regimens are not warranted in patients with malignant lymphomas who have progressive disease after first-line salvage therapy regimens. Br J Haematol (2005) 0.99
Effective gene transfer to solid tumors using different nonviral gene delivery techniques: electroporation, liposomes, and integrin-targeted vector. Cancer Gene Ther (2002) 0.99
A score predicting posttreatment ambulatory status in patients irradiated for metastatic spinal cord compression. Int J Radiat Oncol Biol Phys (2008) 0.98
An immunohistochemical assessment of hypoxia in prostate carcinoma using pimonidazole: implications for radioresistance. Int J Radiat Oncol Biol Phys (2006) 0.98
Reproducibility and correlation between quantitative and semiquantitative dynamic and intrinsic susceptibility-weighted MRI parameters in the benign and malignant human prostate. J Magn Reson Imaging (2010) 0.98
Primary esophageal cancer: heterogeneity as potential prognostic biomarker in patients treated with definitive chemotherapy and radiation therapy. Radiology (2013) 0.96
Phase III intergroup study of fludarabine phosphate compared with cyclophosphamide, vincristine, and prednisone chemotherapy in newly diagnosed patients with stage III and IV low-grade malignant Non-Hodgkin's lymphoma. J Clin Oncol (2006) 0.95
Changes in primary breast cancer heterogeneity may augment midtreatment MR imaging assessment of response to neoadjuvant chemotherapy. Radiology (2014) 0.95
Acute tumor vascular effects following fractionated radiotherapy in human lung cancer: In vivo whole tumor assessment using volumetric perfusion computed tomography. Int J Radiat Oncol Biol Phys (2007) 0.95
A 26-gene hypoxia signature predicts benefit from hypoxia-modifying therapy in laryngeal cancer but not bladder cancer. Clin Cancer Res (2013) 0.94
A phase I trial of radioimmunotherapy with 131I-A5B7 anti-CEA antibody in combination with combretastatin-A4-phosphate in advanced gastrointestinal carcinomas. Clin Cancer Res (2009) 0.94
Modulation of the tumor microvasculature by phosphoinositide-3 kinase inhibition increases doxorubicin delivery in vivo. Clin Cancer Res (2011) 0.93
Carbogen and nicotinamide increase blood flow and 5-fluorouracil delivery but not 5-fluorouracil retention in colorectal cancer metastases in patients. Clin Cancer Res (2006) 0.93
The role of functional imaging in colorectal cancer. AJR Am J Roentgenol (2010) 0.93
Necrosis predicts benefit from hypoxia-modifying therapy in patients with high risk bladder cancer enrolled in a phase III randomised trial. Radiother Oncol (2013) 0.92
Schedule dependence of combretastatin A4 phosphate in transplanted and spontaneous tumour models. Int J Cancer (2002) 0.92
Estimation of apparent tumor vascular permeability from multiphoton fluorescence microscopic images of P22 rat sarcomas in vivo. Microcirculation (2008) 0.91
Functional outcome and survival after radiotherapy of metastatic spinal cord compression in patients with cancer of unknown primary. Int J Radiat Oncol Biol Phys (2006) 0.90
Systemic antiangiogenic activity of cationic poly-L-lysine dendrimer delays tumor growth. Proc Natl Acad Sci U S A (2010) 0.90
The role of hepatocyte-specific contrast agents in hepatobiliary magnetic resonance imaging. Semin Ultrasound CT MR (2013) 0.90
Reproducibility of 2D and 3D fractal analysis techniques for the assessment of spatial heterogeneity of regional blood flow in rectal cancer. Radiology (2012) 0.90
Pre-treatment proliferation and the outcome of conventional and accelerated radiotherapy. Eur J Cancer (2006) 0.90
Prognostic factors for functional outcome and survival after reirradiation for in-field recurrences of metastatic spinal cord compression. Cancer (2008) 0.89
Low dose hyper-radiosensitivity in metastatic tumors. Int J Radiat Oncol Biol Phys (2004) 0.89
Compliance to the prescribed dose and overall treatment time in five randomized clinical trials of altered fractionation in radiotherapy for head-and-neck carcinomas. Int J Radiat Oncol Biol Phys (2003) 0.89
Phase I clinical and pharmacokinetic evaluation of the vascular-disrupting agent OXi4503 in patients with advanced solid tumors. Clin Cancer Res (2012) 0.89
Angiogenesis in non-small cell lung cancer: imaging with perfusion computed tomography. J Thorac Imaging (2010) 0.88
FTIR microspectroscopy of selected rare diverse sub-variants of carcinoma of the urinary bladder. J Biophotonics (2012) 0.88
Halogenated indole-3-acetic acids as oxidatively activated prodrugs with potential for targeted cancer therapy. Bioorg Med Chem Lett (2002) 0.88
Evaluation of functional outcome and local control after radiotherapy for metastatic spinal cord compression in patients with prostate cancer. J Urol (2006) 0.88
Validation of the fluorinated 2-nitroimidazole SR-4554 as a noninvasive hypoxia marker detected by magnetic resonance spectroscopy. Clin Cancer Res (2002) 0.87
Is short-course radiotherapy with high doses per fraction the appropriate regimen for metastatic spinal cord compression in colorectal cancer patients? Strahlenther Onkol (2006) 0.87